EA201890616A1 - Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов - Google Patents

Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов

Info

Publication number
EA201890616A1
EA201890616A1 EA201890616A EA201890616A EA201890616A1 EA 201890616 A1 EA201890616 A1 EA 201890616A1 EA 201890616 A EA201890616 A EA 201890616A EA 201890616 A EA201890616 A EA 201890616A EA 201890616 A1 EA201890616 A1 EA 201890616A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sodium channels
sulphonamide
modulators
connections
controlled sodium
Prior art date
Application number
EA201890616A
Other languages
English (en)
Inventor
Видья Рамдас
Раджешкумар Маганлал Лория
Молой Банерджи
Прадип Ранграо Патил
Адваит Арун Джоши
Лаксмикант Шамлал Датранге
Деепак Сахебрао Валке
Талха Хуссейн Кхан
Амит Кумар Дас
Ганеш Навинчандра Готе
Вайбхав Мадхукар Калхапуре
Венката П. Палле
Раджендер Кумар Камбодж
Original Assignee
Люпин Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Люпин Лимитед filed Critical Люпин Лимитед
Publication of EA201890616A1 publication Critical patent/EA201890616A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к сульфонамидным соединениям формулы (I)где заместители являются такими, как описано в данном документе, и их применению в лекарственном средстве для лечения заболеваний, расстройств, связанных с ингибированием потенциалуправляемых натриевых каналов (VGSC), в частности Na1.7. Также оно относится к соединениям и их фармацевтически приемлемым солям, их фармацевтическим композициям, пригодным при лечении заболеваний, расстройств, синдромов и/или состояний, связанных с ингибированием потенциалуправляемых натриевых каналов (VGSC), в частности Na1.7. Настоящее изобретение также относится к способам получения соединений по настоящему изобретению.
EA201890616A 2015-09-04 2016-09-03 Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов EA201890616A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3420MU2015 2015-09-04
IN201621011342 2016-03-31
PCT/IB2016/055291 WO2017037682A1 (en) 2015-09-04 2016-09-03 Sulfonamide compounds as voltage-gated sodium channel modulators

Publications (1)

Publication Number Publication Date
EA201890616A1 true EA201890616A1 (ru) 2018-08-31

Family

ID=56990675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890616A EA201890616A1 (ru) 2015-09-04 2016-09-03 Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов

Country Status (15)

Country Link
US (1) US10239869B2 (ru)
EP (1) EP3344621A1 (ru)
JP (1) JP2018529668A (ru)
KR (1) KR20180049010A (ru)
CN (1) CN108349957A (ru)
AU (1) AU2016314355A1 (ru)
CA (1) CA2996263A1 (ru)
EA (1) EA201890616A1 (ru)
HK (1) HK1257729A1 (ru)
IL (1) IL257703A (ru)
MX (1) MX2018002746A (ru)
PH (1) PH12018500469A1 (ru)
TW (1) TW201722938A (ru)
WO (1) WO2017037682A1 (ru)
ZA (1) ZA201801501B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
JP2020511511A (ja) * 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CN110885328B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
EP1891063B1 (en) * 2005-05-10 2012-07-25 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
MX2009003876A (es) 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
CA2666143A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046084A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
KR101286323B1 (ko) 2008-10-17 2013-07-15 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (en) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010151597A1 (en) 2009-06-26 2010-12-29 Schering Corporation Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US9334269B2 (en) 2010-02-17 2016-05-10 Amgen Inc. Carboxamides as inhibitors of voltage-gated sodium channels
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US9346798B2 (en) * 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2014201173A1 (en) * 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
MA39778A (fr) * 2014-03-29 2017-02-08 Lupin Ltd Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Also Published As

Publication number Publication date
ZA201801501B (en) 2018-12-19
WO2017037682A1 (en) 2017-03-09
IL257703A (en) 2018-04-30
PH12018500469A1 (en) 2018-09-10
CN108349957A (zh) 2018-07-31
TW201722938A (zh) 2017-07-01
AU2016314355A1 (en) 2018-03-15
CA2996263A1 (en) 2017-03-09
KR20180049010A (ko) 2018-05-10
US20180186777A1 (en) 2018-07-05
HK1257729A1 (zh) 2019-10-25
US10239869B2 (en) 2019-03-26
MX2018002746A (es) 2019-04-25
JP2018529668A (ja) 2018-10-11
EP3344621A1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201991884A3 (ru) Ингибиторы g12c kras
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201691302A1 (ru) Новые гетероциклические соединения
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MY197698A (en) Oxysterols and methods of use thereof
NZ746825A (en) Oxysterols and methods of use thereof
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA202191519A1 (ru) Модуляторы trex1
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201700042A1 (ru) Соединения имидазопиридазина
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201692300A1 (ru) Производные карбоксамида
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
UY36123A (es) Derivados de carboxamida
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида